Akari Therapeutics

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AKTX and other ETFs, options, and stocks.

About AKTX

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor.

CEO

Rachelle Jacques

CEORachelle Jacques

Employees

Employees9

Headquarters

London, Greater London

HeadquartersLondon, Greater London

Founded

2004

Founded2004

Employees

Employees9

AKTX Key Statistics

Market cap

44.31M

Market cap44.31M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

220.10K

Average volume220.10K

High today

$0.60

High today$0.60

Low today

$0.5399

Low today$0.5399

Open price

$0.5782

Open price$0.5782

Volume

73.42K

Volume73.42K

52 Week high

$1.83

52 Week high$1.83

52 Week low

$0.5399

52 Week low$0.5399

AKTX Earnings

-$0.23

-$0.15

-$0.08

$0.00

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Oct 7, Pre-Market

ActualExpected Oct 7, Pre-Market

Akari Therapeutics

Why Robinhood?

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. Show more

AKTX Key Statistics

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor.